Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI) (SUPPORT II)
Pivotal Randomized Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
The objective of this study is to assess the safety and efficacy of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI. Eligible patients will be randomized to undergo HRPCI with either the Supira System (investigational device) or the commercially available Impella systems (comparator device).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The Supira System is a minimally invasive percutaneous ventricular assist device (pVAD) that is intended to provide temporary hemodynamic support (≤ 4 hours) to patients undergoing HRPCI. The Supira Catheter is inserted percutaneously through the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with the pump outlet remaining in the ascending aorta. The pump portion of the Catheter compresses during insertion in the Introducer Sheath and re-expands during use. It actively unloads the left ventricle by pumping blood from the ventricle into the ascending aorta and systemic circulation.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Supira Medical
- Phone Number: (669) 330-0883
- Email: clinical@supiramedical.com
Study Contact Backup
- Name: Chris DeMorett
Study Locations
-
-
California
-
Loma Linda, California, United States, 92354
- Recruiting
- Loma Linda University Medical Center
-
Principal Investigator:
- VInoy Prasad, M.D.
-
Contact:
- Vinoy Prasad, M.D.
- Phone Number: 909-558-4200
- Email: khefflin@llu.edu
-
Sacramento, California, United States, 95817
- Recruiting
- UC Davis
-
Contact:
- Garrett Wong, M.D.
-
Principal Investigator:
- Garrett Wong, M.D.
-
Thousand Oaks, California, United States, 91360
- Recruiting
- Los Robles Regional Medical Center
-
Principal Investigator:
- Saibal Kar, M.D.
-
Contact:
- Saibal Kar, M.D.
- Phone Number: 805-852-9100
- Email: mane.arabyan@hcahealthcare.com
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami
-
Contact:
- Barbara Lang
- Phone Number: 305-243-4950
- Email: blang@med.miami.edu
-
Principal Investigator:
- Aditya Bharadwaj, M.D.
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University Hospital
-
Principal Investigator:
- Bill Nicholson, M.D.
-
Contact:
- Bill Nicholson, M.D.
- Email: wei.xu@emory.edu
-
Atlanta, Georgia, United States, 30309
- Recruiting
- Piedmont Heart Institute
-
Contact:
- David Kandzari, M.D.
-
Principal Investigator:
- David Kandzari, M.D.
-
Lawrenceville, Georgia, United States, 30046
- Recruiting
- Northside Hospital
-
Contact:
- Troy Crain
- Phone Number: 678-312-3828
- Email: Troy.Crain@northside.com
-
Principal Investigator:
- Michele Voeltz, M.D.
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Contact:
- Joaquim Barboza, M.D.
- Phone Number: 312-664-3278
- Email: droshevs@nm.org
-
Principal Investigator:
- Joaquim Barboza, M.D.
-
-
Michigan
-
Detroit, Michigan, United States, 48236
- Recruiting
- Henry Ford Health / St. John Hospital
-
Contact:
- Amir Kaki, M.D.
-
Principal Investigator:
- Amir Kaki, M.D.
-
-
Minnesota
-
Saint Cloud, Minnesota, United States, 56362
- Recruiting
- CentraCare
-
Contact:
- Stephen Kidd, M.D.
-
Principal Investigator:
- Stephen Kidd, M.D.
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Recruiting
- Washington University in St. Louis
-
Principal Investigator:
- John Lasala, M.D.
-
Contact:
- John Lasala, M.D.
- Phone Number: 314-362-1291
- Email: cjenifer@wustl.edu
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Recruiting
- Virtua Health
-
Contact:
- Kristin Wade
- Phone Number: 856-355-1225
- Email: KMWADE@virtua.org
-
Principal Investigator:
- Kintur Sanghvi, M.D>
-
Paramus, New Jersey, United States, 07652
- Recruiting
- The Valley Hospital
-
Contact:
- Kimberly Michel
- Phone Number: 201-447-8453
- Email: KMICHEL@Valleyhealth.com
-
Principal Investigator:
- Raj Tayal, M.D.
-
-
New York
-
Buffalo, New York, United States, 14203
- Recruiting
- University of Buffalo (Buffalo General)
-
Principal Investigator:
- Vijay Iyer, M.D.
-
Contact:
- Vijay Iyer, M.D.
- Phone Number: 716-710-8266
- Email: ehejna@buffalo.edu
-
New York, New York, United States, 10032
- Recruiting
- Cuimc/Nyph
-
Contact:
- Megha Prasad, M.D.
-
Principal Investigator:
- Megha Prasad, M.D.
-
Sub-Investigator:
- Ajay Kirtane, M.D.
-
The Bronx, New York, United States, 10467
- Recruiting
- Montefiore Medical Center
-
Contact:
- Andrea Mignatti, M.D.
-
Principal Investigator:
- Andrea Mignatti, M.D.
-
-
North Carolina
-
Asheville, North Carolina, United States, 28803
- Recruiting
- Mission Health
-
Contact:
- Josie Routhier
- Phone Number: 828-274-6001
- Email: Josephine.Routhier@HCAHealthcare.com
-
Principal Investigator:
- Michael Chenier, M.D.
-
-
Ohio
-
Columbus, Ohio, United States, 43214
- Recruiting
- OhioHealth
-
Principal Investigator:
- Arash Arshi, M.D.
-
Contact:
- Arash Arshi, M.D.
- Phone Number: 614-262-6772
- Email: joanna.flores-jones@ohiohealth.com
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74104
- Recruiting
- Oklahoma Heart Hillcrest Medical
-
Principal Investigator:
- Kamran Muhammad, M.D.
-
Contact:
- Kamran Muhammad, M.D.
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- OHSU
-
Contact:
- Firas Zahr, M.D.
- Phone Number: 503-494-1775
- Email: sampsonna@ohsu.edu
-
Principal Investigator:
- Firas Zahr, M.D.
-
Portland, Oregon, United States, 97225
- Recruiting
- Providence
-
Contact:
- Sheryl Ames
- Phone Number: 503-216-2099
- Email: Sheryl.Ames@providence.org
-
Principal Investigator:
- Kathryn Dawson, M.D.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
Contact:
- Joyce Wald, D.O.
- Phone Number: 215-615-4949
- Email: alyson.brown@pennmedicine.upenn.edu
-
Principal Investigator:
- Joyce Wald, D.O.
-
Principal Investigator:
- Jay Giri, M.D.
-
York, Pennsylvania, United States, 17403
- Recruiting
- Wellspan York Hospital
-
Principal Investigator:
- Rhian Davies, D.O.
-
Contact:
- Rhian Davies, D.O.
- Phone Number: 717-851-5153
- Email: hmckinney@wellspan.org
-
-
South Carolina
-
Columbia, South Carolina, United States, 29203
- Recruiting
- Prisma Health
-
Principal Investigator:
- Vince Vismara, M.D.
-
Contact:
- Vince Vismara, M.D.
- Phone Number: 803-434-3800
- Email: Suzanne.Smith@PrismaHealth.org
-
-
Texas
-
Plano, Texas, United States, 75093
- Recruiting
- Baylor Scott & White The Heart Hospital
-
Principal Investigator:
- Karim Al-Azizi, M.D.
-
Contact:
- Karim Al-Azizi, M.D.
- Phone Number: 469-800-6300
- Email: Osniel.GonzalezRamos@BSWHealth.org
-
-
Utah
-
Murray, Utah, United States, 84107
- Recruiting
- Intermountain Health
-
Contact:
- Savanna Chhak
- Phone Number: 801-507-4731
- Email: Savanna.Chhak@imail.org
-
Principal Investigator:
- Mitul Patel, M.D.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hemodynamically stable and will undergo elective or urgent (not emergent) HRPCI, where hemodynamic support is deemed necessary, as determined by the institutional Heart Team
- Informed consent granted by the subject or legally authorized representative
Exclusion Criteria:
- Cardiogenic shock or acutely decompensated pre-existing chronic heart failure
- Stroke within 6 months of the index procedure, or any prior stroke with permanent neurologic deficit
- Left ventricular thrombus
- Aortic and iliofemoral anatomical conditions that preclude safe delivery and placement of the investigational device or the comparator device
- Ongoing renal replacement therapy with dialysis
- Presence of decompensated liver disease; severe liver dysfunction
- Infection of the proposed procedural access site or active infection
- Known hypersensitivity to intravenous contrast agents that cannot be adequately pre-medicated or known hypersensitivity to heparin, aspirin, adenosine diphosphate (ADP) receptor inhibitors, or nitinol
- Any condition, coagulopathy, planned procedure or contraindication that requires discontinuation of antiplatelet and/or anticoagulant therapy within 90 days of the index procedure
- Breastfeeding or pregnant or planning to become pregnant within 90 days of the HRPCI procedure
- Currently participating in active follow-up phase of another clinical study of an investigational drug or device or planning to enroll in such a study within 90 days of the HRPCI procedure
- Other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to provide written informed consent and/or to comply with study procedures
- Considered to be part of a vulnerable population per the investigator's assessment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Supira System
Subjects receiving the Supira System |
The Supira System is a temporary (≤ 4 hours) ventricular support device indicated for use during elective or urgent HRPCI performed in hemodynamically stable patients with severe coronary artery disease when a heart team has determined HRPCI is the appropriate therapeutic option. |
|
Active Comparator: Impella
Subjects receiving the Impella |
The current commercially available Impella CP with SmartAssist Catheter is indicated for providing temporary (≤ 6 hours) ventricular support during elective or urgent high risk percutaneous coronary i |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite Safety and Efficacy Outcomes
Time Frame: 30 days
|
|
30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Secondary Outcome Measures
Time Frame: 30 and 90 days
|
Individual rates of the following outcomes:
|
30 and 90 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CP-10004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.